株洲千金药业股份有限公司 关于发行股份及支付现金购买资产暨关联交易报告书修订说明的公告

Core Viewpoint - The company plans to acquire 28.92% equity in Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. and 68.00% equity in Hunan Qianjin Xieli Pharmaceutical Co., Ltd. through a combination of issuing shares and cash payment, as part of a related party transaction [1][2]. Group 1 - The company has received approval from the China Securities Regulatory Commission for the issuance of shares to purchase assets [1]. - The announcement includes updates and revisions to the restructuring report compared to the draft disclosed on August 30, 2025 [2]. - The board of directors guarantees the truthfulness, accuracy, and completeness of the announcement [1].